» Articles » PMID: 29390507

Arterial Stiffness Assessment in Patients with Phenylketonuria

Overview
Specialty General Medicine
Date 2018 Feb 3
PMID 29390507
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

In patients with phenylketonuria (PKU) compliant to diet greater tendency to overweight and higher inflammatory biomarkers levels than controls were reported. Although this could lead to atherogenesis, the elastic properties of large arteries in PKU patients have never been assessed. The aim of this study was to assess arterial stiffness measured by applanation tonometry in PKU patients compared to healthy controls.We carried out a cross-sectional study in 41 PKU patients (range age: 6-50 years old) and 41 age- and gender-matched healthy controls. Evaluated data included pharmacological treatment with sapropterin, clinical, and biochemical parameters. Aortic stiffness was assessed noninvasively by applanation tonometry measuring central blood pressure, aortic augmentation index (Aix@HR75), augmentation pressure (AP), and pulse wave velocity (PWV).We found higher PWV in classic PKU patients (6.60 m/second vs 5.26 m/second; P: .044). Percentage of PKU patients with PWV above 90 percentile was higher than controls (14.63% vs 2.32%; P: .048). A positive relationship was observed between the annual Phe median and PWV (r: 0.496; P: .012). PKU subjects with lower Phe tolerance showed more body weight (67.6 kg vs 56.8 kg; P: .012) and more PWV than those with higher Phe tolerance (6.55 m/second vs 5.42 m/second; P: .044).Our data show increased aortic stiffness in PKU patients, measured by applanation tonometry, when compared to healthy controls. Higher Phe levels are associated with a bigger PWV increase, which is not present in those subjects compliant to diet or under sapropterin treatment. These results could have marked effects in both research and clinical daily practice for a proper evaluation of cardiovascular risk in PKU subjects.

Citing Articles

Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria.

Whitehall K, Rose S, Clague G, Ahring K, Bilder D, Harding C Orphanet J Rare Dis. 2024; 19(1):293.

PMID: 39135125 PMC: 11318169. DOI: 10.1186/s13023-024-03203-z.


Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice.

Matuszewska E, Matysiak J, Kaluzny L, Walkowiak D, Plewa S, Dus-Zuchowska M Metabolites. 2024; 14(7).

PMID: 39057720 PMC: 11279192. DOI: 10.3390/metabo14070397.


No evidence for systemic low-grade inflammation in adult patients with early-treated phenylketonuria: The INGRAPH study.

Giret C, Dos Santos Y, Blasco H, Paget C, Gonzalez L, Tressel N JIMD Rep. 2023; 64(6):446-452.

PMID: 37927482 PMC: 10623104. DOI: 10.1002/jmd2.12366.


Expert Consensus on the Long-Term Effectiveness of Medical Nutrition Therapy and Its Impact on the Outcomes of Adults with Phenylketonuria.

Rocha J, Ahring K, Bausell H, Bilder D, Harding C, Inwood A Nutrients. 2023; 15(18).

PMID: 37764724 PMC: 10536918. DOI: 10.3390/nu15183940.


Phenylketonuria (PKU) Urinary Metabolomic Phenotype Is Defined by Genotype and Metabolite Imbalance: Results in 51 Early Treated Patients Using Ex Vivo H-NMR Analysis.

Cannet C, Bayat A, Frauendienst-Egger G, Freisinger P, Spraul M, Himmelreich N Molecules. 2023; 28(13).

PMID: 37446577 PMC: 10343293. DOI: 10.3390/molecules28134916.


References
1.
Schulpis K, Karikas G, Papakonstantinou E . Homocysteine and other vascular risk factors in patients with phenylketonuria on a diet. Acta Paediatr. 2002; 91(8):905-9. DOI: 10.1080/080352502760148612. View

2.
Miras A, Boveda M, Leis M, Mera A, Aldamiz-Echevarria L, Fernandez-Lorenzo J . Risk factors for developing mineral bone disease in phenylketonuric patients. Mol Genet Metab. 2013; 108(3):149-54. DOI: 10.1016/j.ymgme.2012.12.008. View

3.
Hidvegi E, Illyes M, Benczur B, Bocskei R, Ratgeber L, Lenkey Z . Reference values of aortic pulse wave velocity in a large healthy population aged between 3 and 18 years. J Hypertens. 2012; 30(12):2314-21. DOI: 10.1097/HJH.0b013e328359562c. View

4.
Agabiti-Rosei E, Mancia G, ORourke M, Roman M, Safar M, Smulyan H . Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007; 50(1):154-60. DOI: 10.1161/HYPERTENSIONAHA.107.090068. View

5.
Colome C, Artuch R, Lambruschini N, Cambra F, Campistol J, Vilaseca M . Is there a relationship between plasma phenylalanine and cholesterol in phenylketonuric patients under dietary treatment?. Clin Biochem. 2001; 34(5):373-6. DOI: 10.1016/s0009-9120(01)00249-1. View